Posted by Michael Wonder on 10 Aug 2021
GW Pharmaceuticals receives approval for Epidyolex (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex
10 August 2021 - It is estimated that between 3,700 and 11,000 people in the UK live with tuberous sclerosis complex.
GW Pharmaceuticals today announces that the UK Medicines and Healthcare Products Regulatory Agency has approved a new indication for GW's cannabidiol as an adjunctive treatment of seizures associated with tuberous sclerosis complex for patients two years of age and older.
